)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Beijing Tiantan Biological Products
Beijing Tiantan Biological Products (600161) investor relations material
Beijing Tiantan Biological Products Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 2026 revenue was RMB 1.257B, down 7.23% YoY; parent-attributable net income was RMB 129.1M, down 30.65% YoY, as VAT policy changes and lower prices for some products reduced gross profit.
9M revenue was RMB 3.852B, down 13.73% YoY; parent-attributable net income was RMB 428.0M, down 47.72% YoY.
Financial highlights
9M total profit was RMB 750.5M, down 44.30% YoY; operating profit was RMB 754.8M versus RMB 1.354B in 9M 2025.
9M adjusted net income, excluding non-recurring items, was RMB 415.4M, down 48.27% YoY; Q3 adjusted net income was RMB 130.5M, down 29.39% YoY.
9M operating cash flow was RMB 410.2M, up 250.88% YoY; the increase reflected higher bill-discounting proceeds.
Key financial ratios and metrics
Q3 basic and diluted EPS were RMB 0.07, each down 30.65% YoY; 9M basic and diluted EPS were RMB 0.22, each down 47.72% YoY.
Q3 weighted average ROE was 1.08%, down 0.52 percentage points YoY; 9M ROE was 3.59%, down 3.57 percentage points YoY.
Total assets at quarter-end were RMB 16.806B, up 1.34% from year-end 2025; parent shareholders’ equity was RMB 11.871B, up 1.16%.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Beijing Tiantan Biological Products
- Revenue and profit fell over 50% year-over-year amid industry headwinds and policy changes.600161
H1 2026 - Q1 profit and revenue dropped significantly on VAT and price pressures, despite subsidy gains.600161Q1 2026
- Net profit dropped 29.59% on flat revenue as margins and cash flow declined amid policy headwinds.600161H2 2025
- Net profit fell 22.16% year-over-year despite 9.62% revenue growth, with margins under pressure.600161Q3 2025
- Revenue up 9.47%, net profit down 12.88%, with higher dividends and ongoing expansion.600161H1 2025
- Net profit rose 18.52% year-over-year, but Q3 profit declined 7.44%.600161Q3 2024
- Net profit surged 28.12% on higher margins and robust plasma business growth.600161H1 2024
- Revenue up 7.84%, but net profit down 22.90% and operating cash flow negative.600161Q1 2025
- Net profit jumped 39.42% on strong sales and plasma collection growth.600161H2 2024
Next Beijing Tiantan Biological Products earnings date
H2 202626 Mar, 2027
Beijing Tiantan Biological Products
Next Beijing Tiantan Biological Products earnings date
H2 202626 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Beijing Tiantan Biological Products Co., Ltd. is a biopharmaceutical company that develops, manufactures, and distributes a range of blood-based and vaccine products. The company focuses on producing plasma-derived products, including treatments for immune deficiencies and blood coagulation disorders, as well as vaccines for infectious diseases. Utilizing advanced bioprocessing and quality assurance standards, Beijing Tiantan Biological aims to support healthcare needs in China and potentially in international markets. The company is involved in research to expand its product portfolio within the biologics field. Beijing Tiantan Biological Products is headquartered in Beijing, China, and its shares are listed on the Shanghai Stock Exchange.